Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Deepak Kilari"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/b5dc8bfbe1a14acd9235449212e303f7
Autor:
Minal Barve, Ahmad A Tarhini, Deepak Kilari, Rana Mckay, Randy Sweis, Timothy Yap, Justin Gainor, Raghad Karim, Lu Gan, Lan Liu, David Park, Ulka N Vaishampayan, Amna Sher, Sunil Babu, Yawen Ju, Susan Henry
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/3c77a423bbef4fbaa401cdfddf2abaff
Autor:
Minal Barve, Ahmad A Tarhini, Deepak Kilari, Randy Sweis, Timothy Yap, John Clark, Justin Gainor, Lu Gan, Ulka N Vaishampayan, Amna Sher, Yawen Ju, Susan Henry, Stephen DeWall, Asia McCune, Mo Qatanani
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/1c3b6e98b8f34fc1a8e666ad17762f46
Autor:
Hong Zheng, Junjia Zhu, Monika Joshi, Mark Stein, Alexander Sankin, Deepak Kilari, Yousef Zakharia, Joseph Drabick, Ralph Hauke, Hamid Emamekhoo, Todd Schell, Leonard Tuanquin, Vonn Walter, Matthew Kaag, Jiangang Liao, Sheldon L Holder, Suzzane Merrill, Joshua Warrick, Benjamin Gartrel, David J Degraff
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Background Patients with bladder cancer (BC) who are cisplatin ineligible or have unresectable disease have limited treatment options. Previously, we showed targeting programmed death-ligand 1 (PD-L1) with durvalumab (durva) and radiation therapy (RT
Externí odkaz:
https://doaj.org/article/dcfd0deb564b49aea3ec6f5cf657c6a6
Autor:
Bicky Thapa, Gulrayz Ahmed, Aniko Szabo, Mandana Kamgar, Deepak Kilari, Maahum Mehdi, Smitha Menon, Sherin Daniel, Jonathan Thompson, James Thomas, Ben George
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
PurposeThere is variability in utilization of Comprehensive Genomic Profiling (CGP) in most of the metastatic solid tumors (MST). We evaluated the CGP utilization patterns and its impact on outcomes at an academic tertiary center.Patients and Methods
Externí odkaz:
https://doaj.org/article/80abdc4e195d4f0eb41ebce78e03294d
Autor:
Jamie A. Kmak, Nikita Agarwal, Yuting He, Andreas M. Heilmann, Vincent A. Miller, Jeffrey S. Ross, Sumanta Kumar Pal, Siraj M. Ali, Deepak Kilari
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 1, Pp 456-461 (2020)
Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma.
Externí odkaz:
https://doaj.org/article/2ce5d4c419d14d088d5076eeacb1032e
Autor:
Pedro Barata, Whitley Hatton, Arpita Desai, Vadim Koshkin, Ellen Jaeger, Charlotte Manogue, Patrick Cotogno, Malcolm Light, Brian Lewis, Jodi Layton, Oliver Sartor, Arnab Basu, Deepak Kilari, Hamid Emamekhoo, Mehmet A. Bilen
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Introduction: The treatment landscape of metastatic renal cell carcinoma has advanced significantly with the approval of combination regimens containing an immune checkpoint inhibitor (ICI) for patients with treatment-naïve disease. Little informati
Externí odkaz:
https://doaj.org/article/ee841ecd12684cb2a2e43d61a68f0f05
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Metastatic sarcomatoid renal cell carcinoma (sRCC) is an aggressive variant of RCC with generally poor prognosis. Treatment with vascular endothelial growth factor inhibitors or chemotherapy generates only short-lived responses. Recent res
Externí odkaz:
https://doaj.org/article/fd9177e45e5b496a9bd6a6011655fa71
Publikováno v:
Case Reports in Oncology, Vol 10, Iss 3, Pp 897-909 (2017)
With the introduction of immune checkpoint inhibitors into clinical practice, various autoimmune toxicities have been described. Antibodies targeting the receptor:ligand pairing of programmed death receptor-1 (PD-1) and its cognate ligand programmed
Externí odkaz:
https://doaj.org/article/f6cf102d66c64403a8728126b84bcaf0
Autor:
Elizabeth A Guancial, Deepak Kilari, Guang-Qian Xiao, Sohaib H Abu-Farsakh, Andrea Baran, Edward M Messing, Eric S Kim
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0155503 (2016)
BACKGROUND:Platinum (Pt)-based chemotherapy is the standard of care for muscle-invasive bladder cancer (MIBC). However, resistance is a major limitation. Reduced intratumoral drug accumulation is an important mechanism of platinum resistance. Our gro
Externí odkaz:
https://doaj.org/article/2e925e2eec2c40258198aacc2221b937